Pharsight

Torisel patents expiration

TORISEL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722700 PF PRISM CV CCI-779 formulations for parenteral administration
Jul, 2023

(2 months ago)

US8299116 PF PRISM CV CCI-779 concentrate formulations
Jul, 2023

(2 months ago)

US8455539 PF PRISM CV CCI-779 concentrate formulations
Jul, 2023

(2 months ago)

US8722700

(Pediatric)

PF PRISM CV CCI-779 formulations for parenteral administration
Jan, 2024

(4 months from now)

US8299116

(Pediatric)

PF PRISM CV CCI-779 concentrate formulations
Jan, 2024

(4 months from now)

US8455539

(Pediatric)

PF PRISM CV CCI-779 concentrate formulations
Jan, 2024

(4 months from now)

US8026276 PF PRISM CV Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant
Jan, 2026

(2 years from now)

US8026276

(Pediatric)

PF PRISM CV Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant
Jul, 2026

(2 years from now)

US8791097 PF PRISM CV Anti-tumor activity of CCI-779 in papillary renal cell cancer
May, 2032

(8 years from now)

US8791097

(Pediatric)

PF PRISM CV Anti-tumor activity of CCI-779 in papillary renal cell cancer
Nov, 2032

(9 years from now)

Torisel is owned by Pf Prism Cv.

Torisel contains Temsirolimus.

Torisel has a total of 10 drug patents out of which 3 drug patents have expired.

Expired drug patents of Torisel are:

  • US8722700
  • US8299116
  • US8455539

Torisel was authorised for market use on 30 May, 2007.

Torisel is available in solution;intravenous dosage forms.

Torisel can be used as method of treating papillary renal cell carcinoma with temsirolimus, in the absence of interferon alpha.; method of treating metastatic papillary renal cell carcinoma with temsirolimus..

The generics of Torisel are possible to be released after 10 November, 2032.

Drugs and Companies using TEMSIROLIMUS ingredient

Market Authorisation Date: 30 May, 2007

Treatment: Method of treating papillary renal cell carcinoma with temsirolimus, in the absence of interferon alpha.; Method of treating metastatic papillary renal cell carcinoma with temsirolimus.

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of TORISEL before it's drug patent expiration?
More Information on Dosage

TORISEL family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic